A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 1b Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

Trial Profile

A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 1b Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Eptinezumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Alder Biopharmaceuticals
  • Most Recent Events

    • 15 May 2015 According to an Alder Biopharmaceuticals media release, data from this trial were presented at the 17th Congress of the International Headache Society.
    • 15 May 2015 Results published in an Alder Biopharmaceuticals media release.
    • 06 May 2015 Six-month follow-up data will be presented at the 17th Congress of the International Headache Society, according to an Alder BioPharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top